Extrapyramidal symptoms (EPS) are involuntary movement problems caused by medications that block dopamine receptors in the brain. They range from muscle stiffness and tremors to uncontrollable facial movements, and they affect a significant number of people taking antipsychotic medications. In studies of newer antipsychotics, roughly 1 in 5 patients developed some form of EPS within the first year of treatment.
Why These Symptoms Happen
Your brain uses dopamine to coordinate smooth, controlled movement. The basal ganglia, a cluster of structures deep in the brain, act as a movement control center that relies heavily on dopamine signaling. When a medication blocks dopamine receptors in this area, the system loses its ability to fine-tune movement. The result is a range of motor symptoms that the person cannot fully control.
Antipsychotic medications are the most common trigger, but they aren’t the only one. Some anti-nausea drugs (like metoclopramide) and certain antidepressants also block dopamine receptors and can cause the same problems. The risk correlates with how tightly a drug binds to dopamine receptors. Older “first-generation” antipsychotics bind more aggressively, which is why they cause EPS more often than newer ones. But newer medications are far from risk-free: up to 37% of patients taking second-generation antipsychotics report some degree of EPS.
The Four Main Types
EPS isn’t one condition. It’s an umbrella term for four distinct movement problems, each with its own timeline and symptoms.
Acute Dystonia
Dystonia involves sudden, sustained muscle contractions that force the body into abnormal postures. This might look like the neck twisting to one side, the jaw locking open, or the eyes rolling upward and getting stuck. These reactions can be frightening and painful. They tend to hit fast: the vast majority of cases begin within 96 hours of starting or increasing a medication, and symptoms often reach their peak intensity within minutes to hours.
Drug-Induced Parkinsonism
This looks a lot like Parkinson’s disease, with slowness of movement, muscle rigidity, and a rhythmic tremor (typically 3 to 6 cycles per second). The key difference is that it’s caused by medication rather than progressive brain degeneration. It usually shows up within the first few weeks of treatment. About 50 to 75% of cases appear within the first month, and 90% develop within three months.
Akathisia
Akathisia is one of the most distressing forms of EPS. It creates an intense inner restlessness, usually centered in the legs, that makes sitting still feel nearly impossible. People describe it as an unbearable urge to move. From the outside, it looks like constant fidgeting: crossing and uncrossing legs, rocking, pacing, shifting weight from foot to foot. But the internal experience is often worse than what’s visible. The inner tension frequently causes severe anxiety and a deep sense of discomfort that can be difficult to put into words.
Akathisia is a major reason people stop taking their medication. The distress it causes can be so overwhelming that patients would rather go without treatment than endure the feeling. Recognizing it early matters, because it’s often mistaken for worsening anxiety or agitation, which can lead a provider to increase the very medication causing the problem.
Tardive Dyskinesia
Tardive dyskinesia (TD) is the most concerning form of EPS because it develops slowly and can become permanent. It typically appears after at least three months of antipsychotic use, and the risk accumulates over time. With older antipsychotics, roughly 6.5% of patients develop TD per year. Newer antipsychotics carry a lower but still real annual risk of about 2.6%.
TD is characterized by involuntary, repetitive movements, most often in the face: lip smacking, puckering, chewing motions, or the tongue pushing out repeatedly. It can also affect the arms, legs, and trunk with writhing or jerking movements. Unlike the rhythmic tremor of drug-induced parkinsonism, TD movements tend to be irregular and unpredictable. The movements are not under the person’s control, though some people can briefly suppress them with effort.
How EPS Is Detected
Clinicians use a standardized screening tool called the Abnormal Involuntary Movement Scale (AIMS) to check for involuntary movements. It’s a 12-item assessment that systematically evaluates the face (forehead, lips, jaw, tongue), the upper and lower limbs, and the trunk. The examiner also rates the overall severity of movements, how much they interfere with daily functioning, and whether the patient is aware of them. Dental status is included because ill-fitting dentures can mimic some of the mouth and jaw movements seen in TD.
If you’re taking an antipsychotic, you should expect your provider to perform this kind of screening regularly. Many guidelines recommend AIMS assessments every few months for people on older antipsychotics and at least annually for those on newer ones.
How Each Type Is Managed
The approach depends on which type of EPS you’re dealing with, because each has a different underlying pattern.
For acute dystonia, treatment typically works quickly. Medications that restore the dopamine-acetylcholine balance in the brain can relieve muscle contractions, often within minutes when given by injection. Once the acute episode resolves, the triggering medication is usually reduced or switched.
Drug-induced parkinsonism is managed similarly: reducing the dose or switching to a medication with a lighter grip on dopamine receptors. The symptoms are generally reversible once the offending drug is removed or adjusted, though it can take weeks to months for full resolution.
Akathisia is trickier. Dose reduction is the first step, but when the antipsychotic can’t be changed, certain heart-rate-lowering medications (beta-blockers) can ease the restlessness. Some people also respond to medications that target the brain’s balance between dopamine and other signaling systems.
Tardive dyskinesia has historically been the hardest to treat because the movements can persist even after the medication is stopped. In 2017, two medications were approved specifically for TD. These drugs work by a different mechanism, reducing the amount of dopamine packaged and released by nerve cells rather than blocking its receptors. They represent the first targeted treatment for a condition that previously had few good options. Newer formulations, including once-daily dosing, have since become available.
Who Is at Higher Risk
Several factors increase the likelihood of developing EPS. Older adults are more vulnerable, particularly to tardive dyskinesia. Women appear to be at higher risk for TD than men. Higher medication doses and longer treatment durations both increase risk. People who have already experienced one episode of EPS are more likely to have another.
The choice of medication matters significantly. Older antipsychotics cause EPS at roughly 2.5 times the rate of newer ones for tardive dyskinesia alone. But “newer” does not mean “safe.” Individual drugs within the second-generation category vary widely in their tendency to cause movement problems, and some carry risks comparable to older medications at higher doses.
Living With EPS
EPS can affect nearly every aspect of daily life. Tremors and stiffness make routine tasks like eating, writing, or getting dressed more difficult. Akathisia disrupts sleep and concentration. Tardive dyskinesia, with its visible facial movements, often causes significant social embarrassment and self-consciousness, leading some people to withdraw from social situations entirely.
If you notice new involuntary movements, restlessness, muscle stiffness, or tremor after starting or adjusting a psychiatric or anti-nausea medication, bring it up with your provider promptly. Early intervention, especially for tardive dyskinesia, leads to better outcomes. The longer TD goes unaddressed, the less likely it is to fully resolve.